Antithrombotics, thrombolytics, antiplatelets, and coagulants

Foye's Principles of Medicinal Chemistry: Seventh Edition

Volumn , Issue , 2013, Pages 841-876

  Lu, Matthias C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971327173     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (179)

1. Ruff CT, Braunwald E. Will warfarin ever be replaced? J Cardiovasc Pharmacol Ther 2010;15:210-219.
2. Gross PL, Weitz JI. New anticoagulant for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008;28:380-386.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:381S-453S
4. Wright IS. The discovery and early development of anticoagulants: a historical perspective. Circulation 1959;19:73-134.
5. Kakkar VV, Corrigan TP, Spindler J, et al. Efficacy of low doses of heparin in prevention of deep vein thrombosis after major surgery. Lancet 1972;300:101-106.
6. Blanchard E, Ansell J. Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolism. Drugs 2005;65:303-311.
7. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:234S-256S.
8. Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006;96:274-284.
9. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006;134:3-19.
10. Garcia D. Novel anticoagulants and the future of anticoagulation. Thromb Res 2009;4:550-555.
11. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163-1174.
12. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.
13. Lane DA, Lip GYH. Atrial fibrillation and mortality: the impact of antithrombotic therapy. Eur Heart J 2010;31:2075-2076.
14. Nutescu EA, Helgason CM. Concomitant drug, dietary, and lifestyle issues in patients with atrial fibrillation receiving anticoagulation therapy for stroke prophylaxis. Curr Treat Options Cardiovasc Med 2005;7:241-250.
15. Turpie AGG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2007;29:155-165.
16. Khrenov AV, Anayeva NM, Griffin JH, et al. Coagulation pathways in atherothrombosis. Trends Cardiovasc Med 2002;12:317-324.
17. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:265-286.
18. Stryer L. Biochemistry, 3rd Ed. New York: W.H. Freeman and Company, 1988.
19. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-93.
20. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis 2000;30:48-56.
21. Esmon CT. The protein C pathway. Chest 2003;124:26S-32S.
22. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007;109:3161-3172.
23. Brookoff D. Hematologic evaluation. In: Flomenbaum N, Goldfrank L, Jacobson S, eds. Emergency Diagnostic Testing, 2nd Ed. St. Louis, MO: Mosby, 1995.
24. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-233S.
25. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-477.
26. O'Reilly RA. Vitamin K and the oral anticoagulant drugs. Annu Rev Med 1976;27:245-261.
27. Le Cam-Duchez V, Frétigny M, Cailleux N, et al. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets. Thromb Res 2010;126:e235-e237.
28. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S.
29. Wajih N, Sane DC, Hutson SM, et al. Engineering of a recombinant vitamin K-dependent gamma-carboxylation system with enhanced gamma-carboxyglutamic forming capacity: evidence for a functional CXXC redox center in the system. J Biol Chem 2005;280:10540-10547.
30. Valente EJ, Lingafelter EC, Porter WR, et al. Structure of warfarin in solution. J Med Chem 1977;20:1489-1493.
31. USPDI Drug Information for the Health Care Professional, 16th Ed. Rockville, MD: United States Pharmacopeial Convention, Inc., 1996:236-246.
32. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.
33. Baselt RC, ed. Disposition of Toxic Drugs and Chemicals in Man, 5th Ed. Foster City, CA: Chemical Toxicology Institute, 2000.
34. Hollinger BR, Pastoor TP. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med 1993;153:1925-1928.
35. Palmer RB, Alakija P, Cde Baca JE, et al. Fatal brodifacoum rodenticide poisoning: autopsy and toxicologic findings. J Forensic Sci 1999;44:851-855.
36. Redfern R, Gill JE, Hadler MR. Laboratory evaluation of WBA8119 (brodifacoum) as a rodenticide for use against warfarin-resistant and non-resistant rats and mice. J Hygiene 1976;77:419-426.
37. Bachmann KA, Sullivan TJ. Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats. Pharmacology 1983;27:281-288.
38. Laposata M, Van Cott EM, Lev MH. Case 1-2007: a 40-year old women with epistaxis, hematemesis and altered mental status. N Engl J Med 2007;356:174-182
39. Rettie AE, Tai G. The pharmacogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006;6:223-227.
40. Pasmant E, de Beauvoir C, Plessier A, et al. VKROC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis. Thromb Res 2010;126:e134-e136.
41. Spyropoulos AC, Hayth KA, Jenkins P. Anticoagulation with anisindione in a patient with a warfarin-induced skin eruptions. Pharmacotherapy 2003;23:533-536.
42. Linhardt RJ. Heparin: structure and activity. J Med Chem 2003;46:2551-2554.
43. Codée JDC, Overkleeft HS, Van der Marel GA, et al. The synthesis of well-defined heparin and heparin sulfate fragments. Drug Discov Today 2004;1:317-326.
44. Hirsh J, Raschke R. Heparin and low-molecular weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S.
45. De Kort M, Buijsman RC, Van Boeckel CAA. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov Today 2005;10:769-779.
46. Desai UR. New antithrombin-based anticoagulants. Med Res Rev 2004;24:151-181.
47. Jin L, Abrahams JP, Skinner R, et al. The anticoagulant activity of antithrombin by heparin. Proc Natl Acad Sci U S A 1997;94:14683-14688.
48. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
49. Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003;16:54-60.
50. Hovanessian HC. New generation anticoagulants: the low-molecular-weight heparins. Ann Emerg Med 1999;34:768-779.
51. Rosenberg RD. Biochemistry and pharmacology of low-molecular-weight heparin. Semin Hematol 1997;4(Suppl 4):2-8.
52. de Pont AJM, Hofstra JH, Pik DR, et al. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study. Crit Care 2007;11:R102.
53. Kakkar AK. Low- and ultralow-molecular-weight heparins. Best Pract Res Clin Hematol 2004;17:77-87.
54. Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009;123:837-844.
55. Siddiqui MAA, Wagstaff AJ. Enoxaparin-a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients. Drugs 2005;65:1025-1036.
56. Sinnaeve P, Van de Werf F. Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications. Eur Heart J 2010;31:2077-2079.
57. Petitou M, Herault J, Bernat A, et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999;398:417-422.
58. Leone-Bay A, Paton DR, Freeman J, et al. Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin. J Med Chem 1998;41:1163-1171.
59. Eom JS, Koh KS, Al-Hilal TA, et al. Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deosycholic asset on microsurgical anastomosis in rats. Thromb Res 2010;126:e220-e224.
60. Nutescu EA. Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors. Pharmacotherapy 2004;24:82S-87S.
61. Bauer KA. Fondaparinux: a new synthetic and selective inhibitor of factor Xa. Best Pract Res Clin Hematol 2004;17:89-104.
62. Koopman MMW, Buller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003;254:335-342.
63. Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem 1997;40:1600-1607.
64. Cheng JWM. Fondaparinux: a new antithrombotic agent. Clin Ther 2002;24:1757-1769.
65. Dager WE, Andersen J, Nutescu EA. Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing. Pharmacotherapy 2004;7:88S-94S.
66. Hawkins D. Limitation of traditional anticoagulants. Pharmacotherapy 2004;7:62S-65S. 67. Savi P, Herault JP, Duchaussoy P, et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemot 2008;6:1697-1706.
67. Paty I, Trellu M, Destors JM, et al. Reversibility of the anti-Fxa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010;8:722-729.
68. Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007;116:552-560.
69. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115:15-20.
70. Johnson PH. Hirudin: clinical potential of a thrombin inhibitor. Annu Rev Med 1994;45:165-177.
71. Krstenansky JL, Owen TJ, Yates MT, et al. Design, synthesis, and antithrombin activity for conformationally restricted analogues of peptide anticoagulants based on the C-terminal region of the leech peptide, hirudin. Biochim Biophys Acta 1988;957:53-59.
72. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-7101.
73. Nutescu EA, Shapiro, NL. New anticoagulant agents: direct thrombin inhibitors. Clin Geriatr Med 2006;22:33-56.
74. Agnelli G. Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism. Drugs 2004;64:47S-52S.
75. Haas S. Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism. Drugs 2004;64:7S-16S. 77. Nisio MD, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005;353:1028-1040.
76. Eikelboom JW, French J. Management of patients with acute coronary syndromes. What is the clinical role of direct thrombin inhibitors? Drugs 2002;62:1839-1852.
77. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice. Focus on lepirudin. Circulation 2001;103:1479-1484.
78. Matheson AJ, Goa KL. Desirudin: a review of its uses in the management of thrombotic disorders. Drugs 2000;60:679-700.
79. Hirsh J. Current anticoagulant therapy-unmet clinical needs. Thromb Res 2003;109:S1-S8.
80. Levy JH. Novel intravenous antithrombins. Am Heart J 2001;141:1043-1047.
81. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Hematol 2004;17:105-125.
82. Caron MF, McKendall GR. Bivalirudin in percutaneous coronary intervention. Am J Health Syst Pharm 2003;60:1841-1849.
83. Curran MP. Bivalirudin: in patients with ST-segment elevation myocardial infarction. Drugs 2010;70:909-918.
84. Saugel B, Phillip V, Moessmer G, et al. Argatroban therapy for heparininduced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study. Crit Care 2010;14:R90.
85. Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban. J Biol Chem 2002;277: 50439-50449.
86. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/ antithrombotics drugs. Eur J Clin Pharmacol 2002;57:751-758.
87. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22.
88. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008;28:1354-1373.
89. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-399.
90. Imberti D, Dall'Asta C, Pierfranceschi MG. Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med 2009;4:471-477.
91. Turpie AGG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 2007;27:1238-1247.
92. Morell J, Sullivan B, Khalabuda M, et al. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. J Clin Pharmacol 2010;50:986-1000.
93. Lassen MR, Raskob GE, Gallus A, et al; the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-815.
94. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37:74-81.
95. Patrono C, Baigent C, Hirsh J, et al. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:199S-233S.
96. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-2494.
97. Coccheri S. Antiplatelet drugs: do we need new options? Drugs 2010;70:887-908.
98. Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Drugs 2010;70:1771-1783.
99. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonist and atherothrombosis. Eur Heart J 2010;31:17-28.
100. Sztriha LK, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci 2005;229-230:163-169.
101. Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002;99:7634-7639.
102. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005;46:986-993.
103. Matías-Guiu J, Ferro JM, Alvarez-Sabin J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. Stroke 2003;34:1-8.
104. McNeely W, Goa KL. Triflusal. Drugs 1998;55:823-833.
105. Bayón Y, Alonso A, Crespo MS. 4-Trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitor of nuclear factor kB activation. Br J Pharmacol 1999;126:1359-1466.
106. Sanzhez de Miguel L, Jimenez A, Monton M, et al. A 4-trifluoromethyl derivative of salicylate, triflusal, stimulates nitric oxide production by human neutrophils: role in platelet function. Eur J Clin Invest 2000;30:811-817.
107. Eligini S, Violi F, BanfiC, et al. Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. Cardiovas Res 2006;69:218-226.
108. Bhana N, McClellan KJ. Indobufen: an updated review of its use in the management of atherothrombosis. Drugs Aging 2001;18:369-388.
109. Lee S-W, Park S-W, Hong M-K, et al. Triple versus dual antiplatelet therapy after coronary stenting. J Am Coll Cardiol 2005;46:1833-1837.
110. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
111. Lee SW, Park SW, Hong MK, et al. Comparison of cilostazol versus ticlopidine therapy after successful coronary stenting. Am J Cardiol 2005;95:859-862.
112. Ahn JC, Song WH, Kwon JA, et al. Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med 2004;19:230-236.
113. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab 2002;4(Suppl 2):S14-S19.
114. Suri A, Forbes WP, Bramer SL. Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet 1999;37(Suppl 2):61-68.
115. Suri A, Bramer SL. Effect of omeprazole on the metabolism of cilostazol. Clin Pharmacokinet 1999;37(Suppl 2):53-59.
116. Gachet C. The platelet P2 receptor as molecular targets for old and new antiplatelet drugs. Pharmacol Ther 2005;108:180-192.
117. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005;45:1157-1164.
118. Van Giezen JJJ. Opitmizing platelet inhibition. Eur Heart J 2008;10:D23-D29.
119. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008;99:466-472.
120. Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964-1977.
121. Dorsam RT, Murugappan S, Ding Z, et al. Clopidogrel: interactions with the P2Y12 receptor and clinical relevance. Hematology 2003;8:359-365.
122. Cattaneo M. Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development. Eur Heart J 2008;10:133-137.
123. Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 2006;103:11069-11074.
124. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolites of clopidogrel. Thromb Haemost 2000;84:891-896.
125. Ding Z, Kim S, Dorsam RT, et al. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003;101:3908-3914.
126. Dalvie DK, O'Connell TN. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes P450, and monoamine oxidases. Drug Metab Dispos 2004;32:49-57.
127. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373.
128. Duggan ST, Keating GM. Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Drug 2009;69:1707-1726.
129. Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profiles. Cardiovasc Drug Rev 2007;4:357-374.
130. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-1104.
131. Nishiya Y, Hagihara K, Ito T, et al. Mechanism-based inhibition of human cytochrome P-450 2B6 by ticlopidine, clopidogrel, and thiolactone metabolite of prasugrel. Drug Metab Dispos 2009;37:589-593.
132. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010;50:126-142.
133. Veverka A, Hammer JM. Prasugrel: a new thienopyridine inhibitor. J Pharm Pract 2009;22:158-165.
134. Oliphant CS, Doby JB, Das K, et al. Emerging P2Y12 receptor antagonists: role in coronary artery disease. Curr Vasc Pharmacol 2010;8:93-101.
135. Moser M, Bode C. Antiplatelet therapy for atherothrombotic disease: how can we improve the outcomes? J Thromb Thrombolysis 2010;30:240-249.
136. Anderson SD. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Ann Pharmacother 2010;44:524-537.
137. Wallentin L, Becker R, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
138. Dovlatova NL, Jakubowski JA, Sugidachi A, et al. The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008;6:1153-1159.
139. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009;373:919-928.
140. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008;51:3061-3064.
141. Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem 2006;49:5389-5403.
142. Kai Y, Hirano K, Maeda Y, et al. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 2007;38:3259-3265.
143. Proimos G. Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitiors. J Thromb Thrombolysis 2001;11:99-110.
144. Berger PB. The glycoprotein IIb/IIIa inhibitor wars. J Am Coll Cardiovasc 2010;56:476-478.
145. Mousa SA. Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond. Drug Discov Today 1999;4:552-561.
146. Hashemzadeh M, Furukawa M, Goldberry S, et al. Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: a review. Exp Clin Cardiol 2008;13:192-197.
147. Moliterno DJ, Ziada KM. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more option to choose and more time to decide. J Am Coll Cardiol 2008:51:536-537.
148. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-874.
149. Vergara-Jimenez J. Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention. Vascular Health Risk Manage 2010;6:39-45.
150. Genetta TB, Mauro VF. ABCIXIMAB: a new antiaggregant used in angioplasty. Ann Pharmacother 1996;30:251-257.
151. Tam SH, Sassoli PM, Jordan RE, et al. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and avb3 integrins. Circulation 1998;98:1085-1091.
152. Curran MP, Keating GM. Eptifibatide. Drugs 2005;65:2009-2035.
153. Van't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs 2009;69:85-100.
154. Juwana YB, Suryapranata H, Ottervanger JP, et al. Tirofiban for myocardial infarction. Expert Opin Pharmacother 2010;11:861-866.
155. Gresele P, Agnelli G. Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci 2002;23:25-32.
156. De la Cruz JP, Villalobos MA, Escalante R, et al. Effects of the selective inhibition of platelet thromboxane synthase on the platelet-subendothelium interaction. Br J Pharmacol 2002;137:1082-1088.
157. Khan IA, Gowda RM. Clinical perspective and therapeutics of thrombolysis. Int J Cardiol 2003;91:115-127.
158. Baruah DB, Dash RN, Chaudhari MR, et al. Plasminogen activators: a comparison. Vascular Pharmacol 2006;44:1-9.
159. Banerjee A, Chisti Y, Banerjee UC. Streptokinase-a clinically useful thrombolytic agent. Biotechnol Adv 2004;22:287-307.
160. Perler B. Thrombolytic therapies: the current state of affairs. J Endovasc Ther 2005;12:224-232.
161. Hansen AP, Petros AM, Meadows RP, et al. Solution structure of the amino terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994;33:4847-4864.
162. Belkin M, Belkin B, Buckman CA, et al. Intra-arterial fibrinolytic therapy, efficacy of streptokinase vs urokinase. Arch Surg 1986;121:769-773.
163. Antman EM, Braunwald E. Coronary thrombosis. In: Braunwald E, Zipes DP, Libby P, eds. Baunwald's Textbook of Cardiovascular Medicine, 6th Ed. Philadelphia: WB Saunders, 2001:1145-1218.
164. Orsini G, Brandazza A, Sarmientos P, et al. Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies. Eur J Biochem 1991;195:691-697.
165. Ouriel K, Kandarpa K, Schuerr DM, et al. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the purpose trial. J Vasc Interv Radiol 1999;10:1083-1091.
166. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003;89:1358-1362.
167. Bates SM, Greer IA, Hirsh J, et al. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:627S-644S.
168. Liu D, Cheng T, Guo H, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004;10:1379-1383.
169. Rank A, Weigert O, Ostermann H. Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle. Biologics 2010;4:139-145.
170. Schwartz RS. Immune thrombocytopenic purpura: from agony to agonist. N Engl J Med 2007;357:2299-2301.
171. Pruemer J. Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 2009;66:S4-S10.
172. Frampton JE, Lyseng-Williamson KA. Romiplostim. Drugs 2009;69:307-317.
173. Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs 2009;69:567-576.
174. Burzynski J. New options after first-line therapy for chronic immune thrombocytopenic purpura. Am J Health Syst Pharm 2009;66:S11-S23.
175. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-1681.
176. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 2008;371:395-403.
177. Rice L. Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics 2009;3:151-157.
178. Dalmau A, Sabate A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000;91:29-34.
179. Greilich PE, Okada K, Latham P, et al. Aprotinin but not e-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and e-aminocaproic acid. Circulation 2001;104 (Suppl I):265-269